What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.
Tumor biology is rewriting the rules of cancer treatment.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs talks with Dr. Heidi Ko, Director of Medical Affairs at Labcorp and a breast medical oncologist, about the rapid evolution of tumor-agnostic therapies and HER2-targeted treatment strategies.
They unpack what these FDA approvals actually mean in clinical practice, why HER2 is becoming relevant far beyond breast and gastric cancer, and how biomarkers like ERBB2 amplification and HER2 protein expression are shaping decisions across tumor types.
Dr. Ko shares her insights from the DESTINY-PanTumor02 trial, discusses why tissue stewardship is more important than ever, and breaks down what oncologists need to know about interpreting HER2 data across IHC, FISH, and NGS.
Whether you’re navigating biomarker testing workflows or just trying to keep up with precision oncology’s fast pace, this episode offers timely context and clear clinical takeaways.
Tune in now.
Follow Us
Presented by Labcorp Oncology